EMI (Encore Medical) Long-Term Debt: $0.00 Mil (As of Dec. 2025)


What is Encore Medical Long-Term Debt?

Encore Medical EMI Long-Term Debt is $0.00 Mil as of Dec. 2025.

Encore Medical's Long-Term Debt for the quarter that ended in Dec. 2025 was $0.00 Mil.

Encore Medical's quarterly Long-Term Debt stayed the same from Jun. 2025 ($1.00 Mil) to Sep. 2025 ($1.00 Mil) but then declined from Sep. 2025 ($1.00 Mil) to Dec. 2025 ($0.00 Mil).

Encore Medical's annual Long-Term Debt stayed the same from Dec. 2023 ($1.00 Mil) to Dec. 2024 ($1.00 Mil) but then declined from Dec. 2024 ($1.00 Mil) to Dec. 2025 ($0.00 Mil).

Encore Medical  (AMEX:EMI) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Encore Medical Long-Term Debt Related Terms

Encore Medical Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Encore Medical's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Encore Medical Long-Term Debt Chart

Encore Medical Annual Data
Trend Dec23 Dec24 Dec25
Long-Term Debt
1.00 1.00 0.00

Encore Medical Quarterly Data
Dec23 Sep24 Dec24 Jun25 Sep25 Dec25
Long-Term Debt Get a 7-Day Free Trial 0.00 1.00 1.00 1.00 0.00
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of $0.00 Mil mean?
Encore Medical (EMI) has a Long-Term Debt of $0.00 Mil as of Dec. 2025.
Is Encore Medical's Long-Term Debt too high?
Encore Medical's current Long-Term Debt is $0.00 Mil.
How does Encore Medical's Long-Term Debt compare to ?
Encore Medical's Long-Term Debt of $0.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Medical Devices & Instruments company?
A good Long-Term Debt depends on the Medical Devices & Instruments industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Encore Medical's current Long-Term Debt is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Encore Medical stock overvalued right now?
Encore Medical (EMI) has a current Long-Term Debt of $0.00 Mil. The current Long-Term Debt is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Encore Medical (EMI), the current Long-Term Debt is $0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Encore Medical Business Description

Comparable Companies
Address 2975 Lone Oak Drive, Suite 140, Eagan, MN, USA, 55121
Encore Medical Inc develops, manufactures, and markets septal occlusion devices for the repair of certain cardiac defects. Its products have been implanted in approximately 35,000 patients outside the United States. Its closure device is designed to correct a cardiac defect, generally diagnosed in adulthood, known as a patent foramen ovale (PFO). The company also currently market and sell septal occlusion devices for the transcatheter closure of atrial septal defects (ASD).